News

Press Release,Product - RCI-02
RepliCel Announces Dermal Injector Update
Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality...
Press Release
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking...
Press Release
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
Kunihiko Suzuki, one of the leading pioneers in Japan’s emerging regenerative medicine industry, commits to...
Press Release
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
Canadian granting agency MITACS commits to three years of funding for the project’s second stage...
Press Release
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies
Clinical development of RepliCel’s skin rejuvenation and tendon regeneration injectables continues to meet milestones on...
Press Release
RepliCel Adds Independent Director
Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options VANCOUVER, BC – June...
Press Release
RepliCel Launches Testing of Dermal Injector Units
Initial units delivered and first phase of functional testing nearly completeVANCOUVER, BC, CANADA – 25...
Press Release
RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies
Clinical research organization, Accerise Inc., has been retained to work with RepliCel and its other...
Press Release
RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor
Professor Akimichi Morita, Vice Director of Nagoya City University Hospital, will lead RepliCel’s Skin Rejuvenation...
Press Release
RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map
Early identification of unique cell markers is expected to have valuable impact on patents, clinical...
Press Release
RepliCel Announces Record Year in Patents Granted
Patents granted in the United States, China, South Korea, Japan, Israel and New Zealand for...
Press Release
RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)
Professor Tsukasa Kumai, member of the Japan’s Olympic Committee Medical and Scientific Staff, will lead...
Press Release
RepliCel Closes Second Tranche of Strategic Investment Commitment
MainPointe Pharmaceuticals Completes Largest Scheduled Share Purchases per Investment AgreementVANCOUVER, BC, CANADA – 29 April...
Events
RepliCel Presents its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference
Kanagawa Regeneration and Cell Medical Industry Network Organizers Invite RepliCel to Participate in Foreign Company...
Press Release
RepliCel Closes First Tranche of Strategic Investment Commitment
MainPointe Pharmaceuticals Completes Initial Share Purchase per Investment AgreementVANCOUVER, BC, CANADA – 10 February 2021...
Press Release
RepliCel CEO Provides Corporate Update
Targets for 2021 include dermal injector commercial launch, new partnerships, new innovation initiatives, and launch...
Press Release
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration AgreementMainPointe Deal Positions RepliCel for entry...
Press Release
RepliCel Announces Adoption of Advance Notice Bylaw and Shareholder Rights Plan as well as Transitions in its Board of Directors
VANCOUVER, BC, CANADA – December 11, 2020 – RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP)...
Press Release
RepliCel Announces Details of its Annual General Meeting
VANCOUVER, BC, CANADA – December 1, 2020 – RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2)...
Press Release
RepliCel Announces a Binding Term Sheet For Strategic Investment and U.S. Partnership
Transaction represents RepliCel's entrance into the US market Investment terms minimize dilution and puts RepliCel...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.